Allogene Therapeutics (NASDAQ:ALLO), a pioneer in allogeneic "off-the-shelf" CAR-T cell therapy, announced promising interim futility results today from its randomized Phase 2 ALPHA3 trial.
The data highlights the potential of cemacabtagene ansegedleucel (cema-cel) as a first-line consolidation therapy for patients with large B-cell lymphoma (LBCL).
The interim analysis focused on Minimal Residual Disease (MRD), a critical biomarker for long-term remission.
At Day 45, the cema-cel arm achieved a 58.3% MRD negativity rate, compared to just 16.7% in the observation arm—an absolute difference of 41.6%.
The impact on circulating tumor DNA (ctDNA) was even more pronounced.
Patients receiving cema-cel saw a median ctDNA reduction of 97.7%, whereas those in the observation group experienced a 26.6% median increase in tumor markers.
These findings suggest that early intervention with allogeneic CAR-T can effectively clear residual disease following initial chemotherapy.
A standout feature of the trial to date is the safety and tolerability of the "off-the-shelf" product.
Allogene reported zero instances of Cytokine Release Syndrome (CRS), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), or Graft-versus-Host Disease (GvHD).
Furthermore, there were no treatment-related serious adverse events, enabling 10 of the 12 patients in the cema-cel arm to be managed entirely in an outpatient setting.
The ALPHA3 trial is the first of its kind to evaluate CAR-T in the first-line consolidation setting.
By treating patients who are MRD-positive after frontline therapy but before a full clinical relapse, Allogene aims to prevent recurrence entirely rather than treating it once it becomes more aggressive.
Allogene expects to complete enrollment of approximately 220 patients by the end of 2027.
Key upcoming catalysts include an interim Event-Free Survival (EFS) analysis in mid-2027, followed by the primary EFS readout anticipated in mid-2028.